The importance of COPQ for the pharmaceutical industry

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

whitePaper | November 18, 2022

Research by McKinsey on the operational practices of more than 25 global pharmaceutical manufacturers found that the top companies are more than twice as productive as their counterparts.

whitePaper | May 25, 2023

CDER’s mission is to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients. To advance this mission, FDA’s Pharmaceutical Quality for the 21st Century Initiative promotes an efficient, agile, and flexible pharmaceutical manufacturing sector that reliably produces quality drugs without excessive regulatory oversight.

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.